NEWS AND UPDATES

EAP Adopts New Code of Conduct

Tribute to Dr. Martin W. Weber | Retiring from his position at the WHO Regional Office for Europe

EAP Participates in UEMS Spring Council 2025: Key Highlights

EAP World Immunization Week 2025 Featured

EAP Celebrates World Immunization Week April 2025

EAP Welcomes the Updated Declaration of Helsinki

2025 and 2026 – Important Update: EAP, CEPAS and EAP Congress and MasterCourse

Exciting Milestone for Child Health: EAP and WHO Collaborate!

Joint Statement: Attacks on the National Specialized Children’s Hospital in Kyiv on July 8 2024

EAP Supports Call from Canadian Paediatric Society to Prioritize Children’s Needs in Gaza

‘HEALTHY CHILD, HEALTHY WORLD’ DAY

EAP AND EPA REACH AGREEMENT ON A FUTURE COMMON PAEDIATRIC SOCIETY

Joint Statement by EAP, UEMS PS & EPA-UNEPSA – Protecting Children amid Middle East Violence

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative: